Acadia Pharmaceuticals Cash Flow Statement
ACAD / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Acadia Pharmaceuticals generated $110M in operating cash flow and $105M in free cash flow in FY2025. Free cash flow margin was 9.8% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $391.0M | $226.5M | -$61.3M | -$216.0M | -$167.9M | -$281.6M | -$235.3M | -$245.2M | -$289.4M | -$271.4M | -$164.4M | -$20.8M | -$37.9M | -$20.8M | -$22.8M |
| Depreciation & Amortization | $871.0K | $920.0K | $1.5M | $2.0M | $2.2M | $1.5M | $1.3M | $1.5M | $1.2M | $843.0K | $647.0K | $109.0K | $79.0K | $109.0K | $285.0K |
| Operating Cash Flow | $109.8M | $157.7M | $16.7M | -$114.0M | -$125.7M | -$136.2M | -$151.1M | -$167.5M | -$217.8M | -$208.4M | -$121.8M | -$21.6M | -$31.8M | -$21.6M | -$19.9M |
| Capital Expenditures | $4.7M | $523.0K | $50.0K | $0 | $1.1M | $7.6M | $1.1M | $2.1M | $812.0K | $1.5M | $2.1M | $618.0K | $618.0K | - | $3.0K |
| Free Cash Flow | $105.1M | $157.2M | $16.7M | -$114.0M | -$126.8M | -$143.8M | -$152.3M | -$169.6M | -$218.6M | -$209.9M | -$123.9M | -$22.3M | -$32.4M | - | -$19.9M |
| FCF Margin | 9.8% | 16.4% | 2.3% | -22.1% | -26.2% | -32.5% | -44.9% | -75.8% | -175.0% | -1211.2% | -203173.8% | -453.5% | -2828.6% | - | -962.8% |